Predictors of delay in diagnosis and treatment in diffuse large B‐cell lymphoma and impact on survival |
| |
Authors: | Anna Nikonova Hany R. Guirguis Rena Buckstein Matthew C. Cheung |
| |
Affiliation: | 1. Department of Medicine, University of Toronto, Toronto, ON, USA;2. Hematology/Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, ON, USA |
| |
Abstract: | There is a paucity of data on the impact of diagnostic and treatment delays on outcomes in haematological malignancies, particularly in patients with diffuse large B‐cell lymphoma (DLBCL). Our database of patients treated for DLBCL between 2002 and 2010 was interrogated. Univariate and multivariate analyses were performed to determine the relationship between sociodemographic or disease‐specific variables and delays. Cox Regression analysis was used to discern the impact of delays on survival. Patients (n = 278) waited a median of 4 weeks before seeking medical attention. It took a median of 8 weeks for a non‐haematology physician to diagnose DLBCL and refer to a haematologist. A median of 3 weeks elapsed between specialist consultation and chemotherapy initiation. In multivariate logistic regression analysis, bone marrow involvement [odds ratio (OR) = 0·41, P = 0·018], Charlson comorbidity index (OR = 1·42, P = 0·017) and urgent inpatient chemotherapy (OR = 0·40, P = 0·012) were associated with diagnostic delays >6 weeks. Lack of pathological diagnosis at the time of haematology referral was the only factor that independently predicted for treatment delays >4 weeks (OR = 8·25, P < 0·01). Diagnostic or treatment delays did not impact survival or progression‐free survival. In conclusion, selected disease and patient‐related factors are associated with delays in management of DLBCL, but do not impact outcomes. |
| |
Keywords: | non‐Hodgkin lymphoma delay diagnosis treatment targets |
|
|